Top Markets
#1 NEW X CEO IS BACK NEW X CEO IS BACK +80,967.86%
#2 Beta Finance Beta Finance +9,043.03%
#3 Orochi Network Orochi Network +105.17%
#4 Tribe Tribe +69.90%
#5 Chainbase Chainbase +45.67%
#6 Freysa AI Freysa AI +40.65%
#7 BabyBoomToken BabyBoomToken +36.91%
#8 Block Street Block Street +36.41%
#9 Chrema Coin Chrema Coin +27.48%
#10 パンチ (Punch) パンチ (Punch) +20.85%
Coin of the day
NEW X CEO IS BACK NEW X CEO IS BACK
Settings
Language
ENGLISH
Currency
USD
Theme
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rank in Stocks #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Share Price
$0.00244926
Market Cap
$51.67K
Change (1 day)
5.88%
Change (1 year)
110.15%
Country
GB
Trade Nuformix plc (NFX)

Category

Healthcare
Number of shares outstanding for Nuformix plc (NFX)
Number of shares outstanding as of September 2025: 2.03B
According to Nuformix plc latest financial reports and stock price the company's current number of shares outstanding is 2.03B. At the end of September 2024 the company had 787.01M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Nuformix plc (NFX) from 2014 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 2.03B 22.35%
2025 1.66B 111.05%
2024 787.01M 9.39%
2023 719.46M 20.22%
2022 598.45M 3.07%
2021 580.63M 21.71%
2020 477.06M 3.54%
2019 460.75M 23.34%
2018 373.55M 290.13%
2017 95.75M 59.34%
2016 60.09M 0.00%
2014 0.00 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.45B 118.85%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -87.51%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 102.90M -94.94%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M -90.65%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M -76.21%
AU